Summary

Buyer: Gilead Sciences, Inc. (GILD) Last Price: 63.65 Market Cap.: 29.08B
Target: Protherics PLC (ADR) (PTIL) Last Price: 14.24 Market Cap.: 3.45B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 866
Biopharmaceuticals 322
Veterinary Products and Services   7

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 18)
  • HepSera (Adefovir Dipivoxil)
  • Viread (Tenofovir Disoproxil Fumarate)
  • Emtriva (Emtricitabine)
  • Immunostimulatory Sequences Candidate
Target (Total: 7)
  • Angiotensin Vaccine
  • CytoFab
  • Prolarix
  • CroFab [(Crotalidae Polyvalent Immune Fab (Ovine)]
Buyer

n/a
Target
  • Protherics Enfer TSE Diagnostic Kit

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 1)
  • Genelabs Technologies (GNLB)
Target (Total: 1)
  • Symbion Health Limited (SYHTY)
Buyer (Total: 4)
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corp. (ABC)
  • OSI Pharmaceuticals, Inc. (OSIP)
Target (Total: 0)

n/a

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 1,900 214
Revenue Per Employee 1,446,705.0 125,374.4
Total Revenue 685.3 13.2
Total Expenses 320.0 24.4
Other Revenue 0.0 0.0
Cost of Revenue 77.9 6.8
SG&A Expense 151.6 9.3
Research & Development 90.5 8.2
Other Operating Expense 0.0 0.0
Operating Income 365.3 -11.2
Unusual Income 0.0 0.0
LT Debt to Capital 28.9 12.91
Fwd P/E 28.44 n/a
Fwd P/Rev 10.39 n/a
Book Value 3,197.9 49.5
Curr Portion of LTD/Cap Lease 60.2 1.2

Key Ratios

  Buyer Target
Gross Margin % 87.59 36.24
Operating Margin % 54.37 -53.83
Quick Ratio 3.89 1.83
Current Ratio 4.91 2.47
Coverage Ratio 0.07 0
Total Assets 5,179.6 113.0
Return on Equity % 30.92 -36
Return on Assets % 19.09 -15.78
Cash+ ST Inv. Per Share 3.12 1.91
Total Debt 1,360.2 8.6
Total Debt to Equity % 42.54 17.33
Total Debt to Tangible Equity % 42.54 28.38
Debt to Asset % 26.26 7.59

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals > Infectious Diseases > Viral

Target

Focused (): *Healthcare > Biopharmaceuticals

Business Description

Buyer

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. Gilead is a multinational company, with revenues from nine approved products and marketing operations in twelve countries. The Company focuses its research and clinical programs on anti-infectives. Gilead markets Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of human immunodeficiency virus (HIV) infection; Hepsera (adefovir dipivoxil) for the treatment of chronic hepatitis B infection; AmBisome (amphotericin B liposome for injection) for the treatment of fungal infection, and Vistide (cidofovir injection) for the treatment of cytomegalovirus (CMV) infection.

Target

Protherics PLC is a biopharmaceutical company engaged in the development, manufacture and sale of pharmaceutical products for the treatment of human diseases. The Company's core technology is focused on immunotherapeutics and oncology. Immunotherapeutics encompasses the use of antibodies to combat the effects of disease or poisoning. Protherics PLC has manufacturing facilities in Wales, Australia and Salt Lake City, Utah. On December 7, 2005, the Company licensed CytoFab, its product developed for the treatment of sepsis, to AstraZeneca Ireland Operations, a branch in Ireland of AstraZeneca UK Limited (AstraZeneca).

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
  
Veterinary Products and Services  
Veterinary Diagnostics
The Veterinary Diganostics Subsector includes companies that manufacture veterinary diagnostics for the detection and monitoring of veterinary diseases.

Target Products:

  • Protherics Enfer TSE Diagnostic Kit
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Target Products:

  • Angiotensin Vaccine
  
Digestive System  
Liver Disorders  
Hepatitis  
Hepatitis B  
Chronic  
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat hepatitis by inhibiting the action of reverse transcriptase, an enzyme necessary for DNA synthesis using an RNA template.

Buyer Products:

  • HepSera (Adefovir Dipivoxil)
  • Viread (Tenofovir Disoproxil Fumarate)
  • Emtriva (Emtricitabine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Immunostimulatory Sequences Candidate
  • GS 9132
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Protease and Polymerase Inhibitors
  
Hematology  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Small Molecule Therapeutics
  • Protease and Polymerase Inhibitors
  
Immunology  
Immune Deficiency Disorders  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Emtriva (Emtricitabine)
  • Truvada (Tenofovir Disoproxil Fumarate/Emtricitabine)
  • Viread (Tenofovir Disoproxil Fumarate)
  
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 7340 (Non-Nucleotide Reverse Transcriptase Inhibitor)
  • GS 9137 (HIV Integrase Inhibitor)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • GS 9005 (HIV Protease Inhibitor)
  
Infectious Diseases
Mycological (Fungal)  
Antifungal Agents  
Broad Spectrum  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections by increasing permeability of the cell wall causing leakage of cellular contents.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Narrow Spectrum  
Nervous System  
Cryptococcal Meningitis  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the lining of the brain and spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 9137 (HIV Integrase Inhibitor)
  • GS 7340 (Non-Nucleotide Reverse Transcriptase Inhibitor)
  • Immunostimulatory Sequences Candidate
  • GS 9132

Target Products:

  • CytoFab
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Visceral Leishmaniasis  
Polyene Macrolide Antibiotics
Therapeutics that treat infections characterized by Leishmania in macrophages by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • Small Molecule Therapeutics
  • Corus 1040 Inhaled Antibiotic
  • Protease and Polymerase Inhibitors
  • Tamiflu (Oseltamivir Phosphate)
  • GS 9005 (HIV Protease Inhibitor)
  
Viral  
DNA Viruses  
Hepadnavirus  
Hepatitis B  
Chronic  
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months by blocking enzyme essential for viral DNA synthesis.

Buyer Products:

  • Emtriva (Emtricitabine)
  • HepSera (Adefovir Dipivoxil)
  • Viread (Tenofovir Disoproxil Fumarate)
  
RNA Viruses  
Orthomyxovirus  
Influenza A  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir Phosphate)
  
Influenza B  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir Phosphate)
  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Emtriva (Emtricitabine)
  • Viread (Tenofovir Disoproxil Fumarate)
  • Truvada (Tenofovir Disoproxil Fumarate/Emtricitabine)
  
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate)
  
Oncology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Target Products:

  • Prolarix
  
Ophthalmology  
Degenerative Disorders  
Retinitis  
AIDS-Related Cytomegalovirus (CMV) Retinitis  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Vistide (Cidofovir)
  
Pain Management  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.

Buyer Products:

  • Corus Inhaled Lidocaine
  
Respiratory System  
Lower Respiratory Tract Disorders (Lung Disorders)  
Cystic Fibrosis (CF)  
Complications  
Bacterial Infections  
Antibacterial Agents (Antibiotics)  
Monobactams
Therapeutics that treat bacterial infections of the lung resulting as a complication of cystic fibrosis by inhibiting bacterial cell wall synthesis during active multiplication.

Buyer Products:

  • Corus Inhaled Aztreonam Lysine
  
Toxicology  
Animal Poisoning  
Snakes  
Immunoglobulins
Therapeutics that treat snake bites with target specific proteins that neutralize the poison.

Target Products:

  • CroFab [(Crotalidae Polyvalent Immune Fab (Ovine)]
  
Chemical Poisoning  
Digoxin  
Digoxin Binding Agents
Therapeutics that treat toxicity due to ingestion of excessive digoxin by competitively binding to digoxin, making them unavailable for binding at their site of action on cells in the body.

Target Products:

  • DigiFab [Digoxin Immune Fab (Ovine)]
  
Methotrexate  
Carboxypeptidase
Therapeutics that treat methotrexate toxicity by catalyzing its carboxyl groups.

Target Products:

  • Voraxaze
  
Veterinary Products and Services  
Veterinary Diagnostics
The Veterinary Diganostics Subsector includes companies that manufacture veterinary diagnostics for the detection and monitoring of veterinary diseases.

Target Products:

  • Protherics Enfer TSE Diagnostic Kit
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Pfizer Inc. n/a 197,233.738 18.27 13.50 4.17 4.14 9.26
GlaxoSmithKline plc (ADR) n/a 157,749.428 16.17 15.59 3.62 3.73 17.12
Roche Holding Ltd. (ADR) n/a 155,088.732 34.41 24.03 5.61 5.11 8.34
Novartis AG (ADR) n/a 134,289.621 23.59 18.57 3.84 3.66 3.61
AstraZeneca PLC (ADR) n/a 98,768.323 18.17 16.47 3.97 3.83 9.59
Genentech, Inc. n/a 86,373.982 52.80 44.02 11.03 9.68 13.41
Merck & Co., Inc. n/a 86,000.583 15.55 15.78 3.85 3.99 4.90
Abbott Laboratories n/a 74,862.543 24.11 19.57 3.39 3.36 44.96
Bristol Myers Squibb Co. n/a 42,555.965 14.91 18.05 2.20 2.22 8.77
Schering-Plough Corporation n/a 29,715.339 40.38 27.85 2.98 2.90 4.00
Shire plc (ADR) n/a 8,344.273 n/a 29.21 4.93 4.58 10.15
Vertex Pharmaceuticals Incorporated n/a 3,657.027 n/a -16.11 21.67 16.86 20.90
Bausch & Lomb Inc. n/a 2,494.345 16.51 28.33 1.06 1.04 4.37
Valeant Pharmaceuticals International n/a 1,766.630 n/a 52.03 2.04 2.02 -9.29
ViroPharma Incorporated n/a 690.779 5.31 10.73 4.62 3.95 3.01
InterMune, Inc. n/a 550.805 n/a -9.64 5.30 5.80 -90.12
Idenix Pharmaceuticals, Inc. n/a 500.154 n/a -7.80 7.56 6.23 2.77
Incyte Corporation n/a 410.024 n/a -4.79 26.32 15.73 -6.36
Enzon Pharmaceuticals, Inc. n/a 344.196 n/a 13.53 2.07 1.85 -3.03
BioCryst Pharmaceuticals, Inc. n/a 267.579 n/a -5.82 303.17 53.52 5.05
Panacos Pharmaceuticals, Inc. n/a 243.238 n/a -5.71 451.57 716.83 3.41
Trimeris, Inc. n/a 212.624 n/a 96.90 17.79 6.23 9.36
Inspire Pharmaceuticals, Inc. n/a 210.237 n/a -4.95 7.82 5.83 2.00
Metabasis Therapeutics, Inc. n/a 175.549 n/a -4.78 40.37 38.15 1.95
Hollis-Eden Pharmaceuticals Inc. n/a 172.633 n/a -4.63 1,541.03 696.47 3.00

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Genelabs Technologies 81.70% 21.738 n/a n/a 3.18 n/a -27.76
Target
  Symbion Health Limited n/a 1,495.227 24.73 n/a 0.51 n/a 5.19

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Cardinal Health, Inc. 18.00% 28,155.662 28.60 18.49 0.35 0.32 8.05
McKesson Corporation 11.80% 15,589.221 20.81 19.55 0.17 0.16 3.92
AmerisourceBergen Corp. 11.80% 8,802.317 24.36 20.75 0.15 0.15 5.31
OSI Pharmaceuticals, Inc. n/a 2,090.047 n/a -130.36 6.17 4.77 106.01

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Pfizer Inc. n/a 197,233.738 18.27 13.50 4.17 4.14 9.26
GlaxoSmithKline plc (ADR) n/a 157,749.428 16.17 15.59 3.62 3.73 17.12
Roche Holding Ltd. (ADR) n/a 155,088.732 34.41 24.03 5.61 5.11 8.34
Novartis AG (ADR) n/a 134,289.621 23.59 18.57 3.84 3.66 3.61
Merck & Co., Inc. n/a 86,000.583 15.55 15.78 3.85 3.99 4.90
Bristol Myers Squibb Co. n/a 42,555.965 14.91 18.05 2.20 2.22 8.77
Cardinal Health, Inc. n/a 28,155.662 28.60 18.49 0.35 0.32 8.05
McKesson Corporation n/a 15,589.221 20.81 19.55 0.17 0.16 3.92
AmerisourceBergen Corp. n/a 8,802.317 24.36 20.75 0.15 0.15 5.31
OSI Pharmaceuticals, Inc. n/a 2,090.047 n/a -130.36 6.17 4.77 106.01
Medarex, Inc. n/a 1,218.147 n/a -6.69 21.75 24.66 3.31
Genelabs Technologies n/a 21.738 n/a n/a 3.18 n/a -27.76
Praecis Pharmaceuticals n/a 21.231 n/a n/a 3.08 n/a 0.47
Miravant Medical Technologies n/a 0.681 n/a n/a n/a n/a -0.12
Aspen Pharmacare Holdings Ltd n/a n/a n/a n/a n/a n/a n/a
Astellas Pharma Inc. n/a n/a n/a n/a n/a n/a n/a
Achillion Pharmaceuticals, Inc. n/a n/a n/a n/a n/a n/a n/a
Emory University n/a n/a n/a n/a n/a n/a n/a
Target
  AstraZeneca PLC (ADR) n/a 98,768.323 18.17 16.47 3.97 3.83 9.59
Altana AG (ADR) n/a 7,780.441 13.43 13.22 1.75 n/a 4.21
Symbion Health Limited n/a 1,495.227 24.73 n/a 0.51 n/a 5.19
Beacon Pharmaceuticals Ltd. n/a n/a n/a n/a n/a n/a n/a
Cancer Research UK n/a n/a n/a n/a n/a n/a n/a
Enfer Scientific Ltd. n/a n/a n/a n/a n/a n/a n/a
Swedish Orphan AB n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 2,480.9 33.3 2,514.2
Other Revenue 0.0 0.0 0.0
Total Revenue 2,480.9 33.3 2,514.2
Cost of Revenue 307.9 21.2 329.1
SG&A Expense 497.6 17.3 514.9
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 326.5 12.7 339.2
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Total Expenses 1,132.0 51.2 1,183.2
Operating Income 1,348.9 -17.9 1,331.0
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 89.8 -0.1 89.8
Other, Net 0.0 0.0 0.0
Income Before Taxes 1,438.7 -18.0 1,420.7
Income Taxes 450.0 -0.1 449.9
Income After Taxes 988.7 -17.8 970.9
Net Income - Excl. Xord. Items 988.7 -17.8 970.9
Net Income - Incl. Xord. Items 988.7 -17.8 970.9
Income Avail. to Common 988.7 -17.8 970.9
Share Items
Basic Avg. Shares Outstanding 457.5 25.1 482.6
Basic EPS - Excl. Xord. Items 2.16 n/a 2.01
Basic EPS - Incl. Xord. Items 2.16 n/a 2.01
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 476.2 25.1 501.3
F.D. EPS - Excl. Xord. Items 2.08 n/a 1.94
F.D. EPS - Incl. Xord. Items 2.08 n/a 1.94
Balance Sheet
Assets
Cash and Equivalents 884.4 47.8 932.3
ST Investments 603.1 0.0 603.1
Accounts Receivable 489.3 9.8 499.2
Inventory 318.7 20.5 339.2
Prepayments and Advances 37.5 0.0 37.5
Other Current Assets 158.7 0.0 158.7
Current Assets 2,491.9 78.1 2,570.0
Accum D&A 0.0 0.0 0.0
PPE, Net 253.8 15.2 269.0
Goodwill & Intangibles 0.0 19.3 19.3
Long Term Investments 1,813.4 0.0 1,813.4
Other Assets 0.0 0.0 0.0
Other LT Assets 620.6 0.4 621.0
Total Assets 5,179.6 113.0 5,292.7
Liabilities
Accounts Payable 153.8 29.6 183.4
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 221.8 0.0 221.8
ST Debt 0.0 0.1 0.1
Curr Port of LTD & Cap Lease Oblg 60.2 1.2 61.4
Other (Current) Liabilities 72.1 0.8 72.9
Current Liab. 508.0 31.6 539.5
LT Debt 1,300.0 5.1 1,305.1
Capitalized Lease Obligations 0.0 2.3 2.3
Total LT Debt 1,300.0 7.3 1,307.3
Other LT Liab. 173.8 24.6 198.4
Total Liabilities 1,981.7 63.5 2,045.2
Shareholders Equity
Common Stock 0.5 9.7 10.2
Additional Paid in Capital 2,386.4 163.1 2,549.5
Retained Earnings 826.4 -122.9 703.5
Other Equity -15.4 -0.4 -15.7
Total Equity 3,197.9 49.5 3,247.4
Total Liab. & Equity 5,179.6 113.0 5,292.7
Shares Outstanding 456.3 25.9 482.2
Cash Flow
Operating Cash Flow
CF Net Income 988.7 -17.9 970.8
CF Depreciation 36.5 2.6 39.2
CF Amortization 10.5 0.2 10.7
CF Deferred Taxes -120.4 0.0 -120.4
Other Non-Cash Items 227.4 1.6 229.0
Change in Working Capital -455.8 37.1 -418.8
Total Cash From Operating Activities 686.8 23.6 710.5
Investing Cash Flow (not calculated)
Capital Expenditures -57.9 -3.7 -61.7
Other Investing Cash Flows -1,505.1 1.3 -1,503.8
Total Cash From Investing Activities -1,563.0 -2.4 -1,565.5
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock -401.0 15.1 -385.8
Purchase and Retirement of Debt 1,474.9 -1.1 1,473.8
Other Financing Cash Flow -94.3 -0.7 -95.1
Total Cash From Financing Activities 979.6 13.0 992.5
Exchange Rate Effects -12.5 0.0 -12.5
Net Change in Cash 90.8 34.2 125.0
Cash Taxes Paid 151.4 0.1 151.5
Cash Interest Paid 0.1 0.7 0.8